FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1

Immune-checkpoint blockade (ICB) therapies have been widely used in clinical treatment of cancer patients, but only 20–30% of patients benefit from immunotherapy. Therefore, it is important to decipher the molecular mechanism of resistance to ICB and develop new combined treatment strategies. PD-L1...

Full description

Bibliographic Details
Main Authors: Chaoqin Guo, Nana Zhou, Yisong Lu, Mingshan Mu, Zilin Li, Xu Zhang, Linglan Tu, Jingyang Du, Xiangyu Li, Dongsheng Huang, Qiuran Xu, Xiaoliang Zheng
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223017535